Selumetinib sulfate

硫酸氢司美替尼

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameSelumetinib sulfate
Drug Alias Name舍美替尼Selumetinib Sulfateselumetinibum司美替尼Selumetinib hydrogen sulfate +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerSkin Melanoma +[93] 
Global Approved IndicationsNeurofibromatosis 1Neurofibroma, Plexiform
Approved Indications in ChinaNeurofibromatosis 1
Original Approved Country/TerritoryUnited States
Original Approved Date2020/04/10
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteAstrazeneca Pharmaceutical Co LtdAstrazeneca Uk Ltd +[15] 
Inactive CompaniesThe Netherlands Cancer InstituteOhsu Knight Cancer InstituteUniversity College London +[8] 
Active IndicationsMetastatic breast cancerLow-grade GliomaPoorly Differentiated Thyroid Gland Carcinoma +[51] 
Inactive IndicationsUveal melanomaSkin MelanomaMyelodysplastic Syndromes +[42] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG